Is Savara Inc. (SVRA) a Buy, Sell, or Hold?
NASDAQ : SVRA
Savara Inc.
$5.43 USD
-$0.08 (-1.45%)
- Volume
- 3.79M
- Average Volume
- 1.69M
- Market Capitalization
- $1.11B
- P/E Ratio
- -9.70
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $7.01
- Year Low
- $2.43
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.47
Company Overview
NASDAQ
Matthew Pauls
Biotechnology
Healthcare
SVRA
70
US
USD
Liquidity Metrics
0.17
13.47
13.47
2.50
0.00
Sales & Valuation
-$
0.00
7.81
-10.40
-0.42
Profitability
-$0.53
-$118.84M
0.00%
0.00%
-87.19%
-58.42%
P/E Metrics
-9.70
0.73
0.73
Analyst Price Target & Rating
$10.00
$10.00
$10.00
1/5
11 Analysts
-45.70%
Financial Health Scores
9.90
1/9
$193.73M
$221.64M
$45.61M
-$129.48M
Key Metrics (TTM)
$1.12B
0.00
-8.67
13.47
-87.19%
-65.06%
-9.28%
-9.47%
-78 days
Company Executives
| Name | Title |
|---|---|
| Brian Robinson | Executive Vice President of Global Medical Affairs |
| Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs |
| Kate McCabe | Chief Legal Officer |
| Anne Erickson | Chief Business & Corporate Affairs Officer |
| Brian Maurer | Head of Clinical Operations |
| Siddharth J. Advant | Executive Vice President of Global Technical Operations |
| Matthew Pauls | Chairman & Chief Executive Officer |
| Yasmine Wasfi | Chief Medical Officer |
| David L. Lowrance | Chief Financial & Administrative Officer and Secretary |
| Robert Lutz | Chief Operating Officer |
Poll Results
No votes yet today — be the first to share your view!
About Savara Inc. (NASDAQ:SVRA) Stock
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas. ...
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 10:26:09
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
2026-06-27 11:14:09
394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted average price of around $5.68 per share. This transaction represented 42.40% of the executive's total common stock holdings pre-transaction.
Savara Announces New Employment Inducement Grant
2026-06-12 16:05:00
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company's common stock, restricted stock units (RSUs) cov.
Savara Announces Chief Financial and Administrative Officer Transition
2026-06-08 16:05:00
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, M.B.A., the Company's Chief Operating Offic.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
2026-05-27 16:05:00
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company's c.
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
2026-05-27 07:52:14
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, with MOLBREEVI targeting autoimmune PAP. SVRA's cash runway extends into H2 2027, bolstered by $203M in liquidity and up to $150M in non-dilutive capital upon FDA approval. Regulatory momentum is strong: MOLBREEVI has Priority Review, with a PDUFA date set for November 22, 2026, and positive Phase 3 data supporting efficacy.
2026-05-20 09:00:00
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at t
2026-05-20 08:15:00
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: “Rel.
Frequently Asked Questions
-
What is the current Savara Inc. (SVRA) stock price?
-
Savara Inc.(NASDAQ:SVRA) stock price is $5.43 in the last trading session. During the trading session, SVRA stock reached the peak price of $7.005 while $2.43 was the lowest point it dropped to. The percentage change in SVRA stock occurred in the recent session was --1.45% while the dollar amount for the price change in SVRA stock was -$0.08.
-
SVRA's industry and sector of operation?
-
The NASDAQ listed SVRA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SVRA?
-
Brian Robinson | Executive Vice President of Global Medical Affairs
Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs
Kate McCabe | Chief Legal Officer
Anne Erickson | Chief Business & Corporate Affairs Officer
Brian Maurer | Head of Clinical Operations -
How many employees does SVRA have?
-
Number of SVRA employees currently stands at 70. SVRA operates from Building III, Langhorne, PA 78746, US.
-
Link for SVRA official website?
-
Official Website of SVRA is: https://www.savarapharma.com
-
How do I contact SVRA?
-
SVRA could be contacted at phone #512 614 1848 and can also be accessed through its website. SVRA operates from Building III, Langhorne, PA 78746, US.
-
How many shares of SVRA are traded daily?
-
The average number of SVRA shares traded daily for last 3 months was 1.69M.
-
What is the market cap of SVRA currently?
-
The market value of SVRA currently stands at $1.11B with its latest stock price at $5.43